Compile Data Set for Download or QSAR
maximum 50k data
Found 5360 Enz. Inhib. hit(s) with Target = 'Monoglyceride lipase'
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM150300(US8987247, 1)
Affinity DataKd:  1.40nMAssay Description:The ThermoFluor (TF) assay is a 384-well microplate-based binding assay that measures thermal stability of proteins1,2. The experiments were carried ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50567001(CHEMBL4873898)
Affinity DataKd:  1.5nMAssay Description:Binding affinity to human His-tagged MAGL assessed as dissociation constant by surface plasmon resonance assayMore data for this Ligand-Target Pair
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50569386(CHEMBL1356127)
Affinity DataKd:  710nMAssay Description:Binding affinity to MAGL (unknown origin) by SPR analysisMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50574655(CHEMBL4852896)
Affinity DataKi:  1.10nMAssay Description:Inhibition of human recombinant MAGL assessed as dissociation constant using 4-NPA as substrateMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50574656(CHEMBL4866490)
Affinity DataKi:  1.10nMAssay Description:Inhibition of human recombinant MAGL assessed as dissociation constant using 4-NPA as substrateMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50574654(CHEMBL4870906)
Affinity DataKi:  1.10nMAssay Description:Inhibition of human recombinant MAGL assessed as dissociation constant using 4-NPA as substrateMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50605682(CHEMBL5176915)
Affinity DataKi:  1.40nMAssay Description:Competitive inhibition of human recombinant MAGL using 4-nitrophenylacetate as substrate assessed as inhibition constant by Michaelis-Menten analysisMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50562160(CHEMBL4757403)
Affinity DataKi:  11nMAssay Description:Competitive inhibition of human recombinant MAGL using varying concentration of 4-nitrophenylacetate as substrate incubated for 30 mins by microplate...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50540526(CHEMBL4637658)
Affinity DataKi:  13nMAssay Description:Competitive inhibition of human recombinant MAGL at 31.25 nM to 125 nM pre-incubated for 5 mins before MAGL substrate addition and further incubated ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50562158(CHEMBL4747585)
Affinity DataKi:  27nMAssay Description:Competitive inhibition of human recombinant MAGL using varying concentration of 4-nitrophenylacetate as substrate incubated for 30 mins by microplate...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50562161(CHEMBL4755606)
Affinity DataKi:  30nMAssay Description:Competitive inhibition of human recombinant MAGL using varying concentration of 4-nitrophenylacetate as substrate incubated for 30 mins by microplate...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50562159(CHEMBL4798508)
Affinity DataKi:  37nMAssay Description:Competitive inhibition of human recombinant MAGL using varying concentration of 4-nitrophenylacetate as substrate incubated for 30 mins by microplate...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50531972(CHEMBL4536045)
Affinity DataKi:  39nMAssay Description:Competitive inhibition of human recombinant MAGL using 4-NPA as substrate after 30 mins by Michaelis-Menten-based plot analysisMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50600140(CHEMBL5174588)
Affinity DataKi:  60nMAssay Description:Mixed inhibition MAGL (unknown origin) using 4-nitrophenyl acetate as substrate by Dixon plot analysisMore data for this Ligand-Target Pair
In DepthDetails PubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50394369(CHEMBL2159781)
Affinity DataKi:  75.7nMAssay Description:Irreversible inhibition of human MAGL using p-nitrophenylpropionate as substrateMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50255235(CHEMBL4078924)
Affinity DataKi:  412nMAssay Description:Competitive inhibition of recombinant human MAGL using 4-NPA as substrate after 30 mins by Michaelis-Menten plot analysisMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50470454(CHEMBL4282040)
Affinity DataKi:  650nMAssay Description:Competitive inhibition of human recombinant MAGL using 4-NPA substrate incubated for 30 mins by Michaelis-Menten kinetics analysisMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Rattus norvegicus (Rat))
University Of Athens

Curated by ChEMBL
LigandPNGBDBM50274152((2S,9Z)-octadec-9-ene-1,2-diamine dihydrochloride ...)
Affinity DataKi:  2.18E+4nMAssay Description:Inhibition of Sprague-Dawley rat MGLMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Rattus norvegicus (Rat))
University Of Athens

Curated by ChEMBL
LigandPNGBDBM50274153((2R,9Z)-octadec-9-ene-1,2-diamine dihydrochloride ...)
Affinity DataKi:  3.90E+4nMAssay Description:Inhibition of Sprague-Dawley rat MGLMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50379241(CHEMBL2011479)
Affinity DataKi:  4.00E+4nMAssay Description:Non-competitive inhibition of human recombinant MAGL assessed as 7-hydroxycoumarin level using umbelliferyl arachidonate as substrate by luminescence...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Rattus norvegicus (Rat))
University Of Athens

Curated by ChEMBL
LigandPNGBDBM50274151(CHEMBL473249 | hexadecane-1,2-diamine dihydrochlor...)
Affinity DataKi:  5.87E+4nMAssay Description:Inhibition of Sprague-Dawley rat MGLMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50479142(Guineensine | Guineesine | Pipyahyine)
Affinity DataKi: >1.00E+5nMAssay Description:Inhibition of MAGL in human U937 cell homogenates using [3H]-2OG as substrate preincubated for 15 mins followed by substrate addition and measured af...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50393668(CHEMBL2158989)
Affinity DataIC50:  155nMAssay Description:Inhibition of human recombinant MAGL using [3H]-2-OG as substrate after 10 mins by liquid scintillation counterMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50393669(CHEMBL2158903)
Affinity DataIC50: >1.00E+6nMAssay Description:Inhibition of human recombinant MAGL using [3H]-2-OG as substrate after 10 mins by liquid scintillation counterMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50393670(CHEMBL2158904)
Affinity DataIC50:  2.95E+4nMAssay Description:Inhibition of human recombinant MAGL using [3H]-2-OG as substrate after 10 mins by liquid scintillation counterMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50393671(CHEMBL2158905)
Affinity DataIC50: >1.00E+6nMAssay Description:Inhibition of human recombinant MAGL using [3H]-2-OG as substrate after 10 mins by liquid scintillation counterMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50393672(CHEMBL2158906)
Affinity DataIC50:  2.19E+4nMAssay Description:Inhibition of human recombinant MAGL using [3H]-2-OG as substrate after 10 mins by liquid scintillation counterMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50393673(CHEMBL2158907)
Affinity DataIC50: >1.00E+6nMAssay Description:Inhibition of human recombinant MAGL using [3H]-2-OG as substrate after 10 mins by liquid scintillation counterMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50393674(CHEMBL2158908)
Affinity DataIC50: >1.00E+6nMAssay Description:Inhibition of human recombinant MAGL using [3H]-2-OG as substrate after 10 mins by liquid scintillation counterMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50393675(CHEMBL2158909)
Affinity DataIC50: >1.00E+6nMAssay Description:Inhibition of human recombinant MAGL using [3H]-2-OG as substrate after 10 mins by liquid scintillation counterMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50393676(CHEMBL2158910)
Affinity DataIC50: >1.00E+6nMAssay Description:Inhibition of human recombinant MAGL using [3H]-2-OG as substrate after 10 mins by liquid scintillation counterMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50393677(CHEMBL2158911)
Affinity DataIC50:  9.55E+4nMAssay Description:Inhibition of human recombinant MAGL using [3H]-2-OG as substrate after 10 mins by liquid scintillation counterMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50393678(CHEMBL2158912)
Affinity DataIC50: >1.00E+6nMAssay Description:Inhibition of human recombinant MAGL using [3H]-2-OG as substrate after 10 mins by liquid scintillation counterMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50393679(CHEMBL2158913)
Affinity DataIC50: >1.00E+6nMAssay Description:Inhibition of human recombinant MAGL using [3H]-2-OG as substrate after 10 mins by liquid scintillation counterMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50393680(CHEMBL2158914)
Affinity DataIC50:  6.92E+4nMAssay Description:Inhibition of human recombinant MAGL using [3H]-2-OG as substrate after 10 mins by liquid scintillation counterMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50393681(CHEMBL2158915)
Affinity DataIC50: >1.00E+6nMAssay Description:Inhibition of human recombinant MAGL using [3H]-2-OG as substrate after 10 mins by liquid scintillation counterMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50393682(CHEMBL2158916)
Affinity DataIC50: >1.00E+6nMAssay Description:Inhibition of human recombinant MAGL using [3H]-2-OG as substrate after 10 mins by liquid scintillation counterMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50393683(CHEMBL2158917)
Affinity DataIC50:  7.41E+3nMAssay Description:Inhibition of human recombinant MAGL using [3H]-2-OG as substrate after 10 mins by liquid scintillation counterMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50393684(CHEMBL2158918)
Affinity DataIC50:  355nMAssay Description:Inhibition of human recombinant MAGL using [3H]-2-OG as substrate after 10 mins by liquid scintillation counterMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50393685(CHEMBL2158919)
Affinity DataIC50:  1.78E+3nMAssay Description:Inhibition of human recombinant MAGL using [3H]-2-OG as substrate after 10 mins by liquid scintillation counterMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50393686(CHEMBL2158920)
Affinity DataIC50:  4.27E+3nMAssay Description:Inhibition of human recombinant MAGL using [3H]-2-OG as substrate after 10 mins by liquid scintillation counterMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50393687(CHEMBL2158921)
Affinity DataIC50:  5.13E+3nMAssay Description:Inhibition of human recombinant MAGL using [3H]-2-OG as substrate after 10 mins by liquid scintillation counterMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50393688(CHEMBL2158922)
Affinity DataIC50:  2.40E+3nMAssay Description:Inhibition of human recombinant MAGL using [3H]-2-OG as substrate after 10 mins by liquid scintillation counterMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50393689(CHEMBL2158923)
Affinity DataIC50:  3.72E+3nMAssay Description:Inhibition of human recombinant MAGL using [3H]-2-OG as substrate after 10 mins by liquid scintillation counterMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50393690(CHEMBL2158924)
Affinity DataIC50:  6.03E+3nMAssay Description:Inhibition of human recombinant MAGL using [3H]-2-OG as substrate after 10 mins by liquid scintillation counterMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50393691(CHEMBL2158925)
Affinity DataIC50:  3.02E+3nMAssay Description:Inhibition of human recombinant MAGL using [3H]-2-OG as substrate after 10 mins by liquid scintillation counterMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50393692(CHEMBL2158926)
Affinity DataIC50:  2.63E+3nMAssay Description:Inhibition of human recombinant MAGL using [3H]-2-OG as substrate after 10 mins by liquid scintillation counterMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50393693(CHEMBL2158927)
Affinity DataIC50:  2.00E+3nMAssay Description:Inhibition of human recombinant MAGL using [3H]-2-OG as substrate after 10 mins by liquid scintillation counterMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50393694(CHEMBL2158928)
Affinity DataIC50:  2.19E+3nMAssay Description:Inhibition of human recombinant MAGL using [3H]-2-OG as substrate after 10 mins by liquid scintillation counterMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMonoglyceride lipase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50393695(CHEMBL2158929)
Affinity DataIC50:  5.37E+3nMAssay Description:Inhibition of human recombinant MAGL using [3H]-2-OG as substrate after 10 mins by liquid scintillation counterMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Displayed 1 to 50 (of 5360 total ) | Next | Last >>
Jump to: